Core Viewpoint - Shanghai Kangpeng Technology Co., Ltd. has received approval from the UK Medicines and Healthcare products Regulatory Agency for a drug aimed at treating moderate to severe vasomotor symptoms (VMS) related to menopause, marking a significant advancement in women's health and demonstrating the company's strategic positioning in the pharmaceutical sector [1] Group 1: Technological Foundation - The approved drug is the world's first dual neurokinin (NK) targeted therapy, overcoming limitations of traditional hormone therapies and non-hormonal drugs [2] - The development of the core intermediate relies on Kangpeng's two decades of expertise in fluorination and carbon-carbon coupling technologies, enhancing drug targeting and metabolic stability [2] - As of the end of 2024, Kangpeng has accumulated 115 patents, including 66 invention patents, showcasing its robust technological foundation for pharmaceutical intermediate development [2] Group 2: Collaborative Model - The successful approval of the drug reflects Kangpeng's long-standing collaboration model with pharmaceutical companies, engaging in the early stages of drug development and expanding supply as the drug progresses to commercialization [3] - Kangpeng's client base includes renowned pharmaceutical companies such as Merck, Eli Lilly, and Bayer, indicating strong industry partnerships [3] - The drug's application for market approval is currently under review in major markets like the US and EU, with potential for significant revenue growth if approved [3] Group 3: Market Potential and Strategic Layout - VMS is a common symptom affecting 80% of women in the menopausal transition, highlighting a substantial market opportunity for new treatment options [5] - The global market for VMS treatments is projected to reach approximately $4.2 billion (around 30 billion RMB) in 2024, with an expected growth to $11.29 billion (around 80 billion RMB) by 2037, reflecting a compound annual growth rate of 7.9% [5] - Kangpeng's intermediate supply capabilities position the company to capitalize on this market growth, reinforcing its dual-track strategy and vision to become a leader in the fine chemicals sector in China [5][6] Group 4: Strategic Synergy - The company is expanding capacity in the new materials sector while simultaneously enhancing its pharmaceutical CDMO business through core technology transformation [6] - This synergy is expected to boost CDMO revenue in the short term and establish a more resilient long-term growth trajectory by engaging with multinational pharmaceutical companies and exploring new markets [6]